Neoadjuvant FOLFIRINOX With Losartan Followed by Chemoradiotherapy in Advanced Pancreatic Cancer
This single-arm phase 2 clinical trial evaluates the margin-negative resection rate in locally advanced pancreatic cancer after neoadjuvant FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) and losartan therapy and individualized chemoradiotherapy.